NAVIGATOR trial to study nateglinide/valsartan for diabetes and cardiovascular disease prevention June 25, 2001
Initiation of phase III trials of TSE-424 triggers milestone payment from Wyeth to Ligand June 25, 2001
AT-1015, a 5-HT2 antagonist, improves nerve blood flow and sensory/motor deficits in diabetic rats June 25, 2001
RSS